Microport Cardioflow Medtech Corp
HKEX:2160
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Microport Cardioflow Medtech Corp
Total Liabilities & Equity
Microport Cardioflow Medtech Corp
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Microport Cardioflow Medtech Corp
HKEX:2160
|
Total Liabilities & Equity
¥2.7B
|
CAGR 3-Years
83%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Total Liabilities & Equity
¥3.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Total Liabilities & Equity
¥16.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Total Liabilities & Equity
¥59.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Andon Health Co Ltd
SZSE:002432
|
Total Liabilities & Equity
¥29B
|
CAGR 3-Years
9%
|
CAGR 5-Years
61%
|
CAGR 10-Years
42%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Total Liabilities & Equity
¥28B
|
CAGR 3-Years
39%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Microport Cardioflow Medtech Corp
Glance View
MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-02-04. The firm is mainly engaged in the development and commercialization of transcatheter and surgical solutions for valvular heart diseases. The firm's main products include the first-generation transcatheter aortic heart valve implantation (TAVI) product VitaFlow and the second-generation TAVI product VitaFlow II. The firm mainly conducts business within the domestic market.
See Also
What is Microport Cardioflow Medtech Corp's Total Liabilities & Equity?
Total Liabilities & Equity
2.7B
CNY
Based on the financial report for Dec 31, 2025, Microport Cardioflow Medtech Corp's Total Liabilities & Equity amounts to 2.7B CNY.
What is Microport Cardioflow Medtech Corp's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
19%
Over the last year, the Total Liabilities & Equity growth was 0%. The average annual Total Liabilities & Equity growth rates for Microport Cardioflow Medtech Corp have been 83% over the past three years , 19% over the past five years .
